GenFleet Therapeutics to Present Phase I Data for GFH312 at 2023 American Society for Clinical Pharmacology & Therapeutics Meeting

2023-03-09

临床1期临床2期临床申请AACR会议ASCO会议

SHANGHAI, March 9, 2023 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the results from phase I study of GFH312 (RIPK1 inhibitor RIPK1 inhibitor) monotherapy will be presented as a poster at the 2023 ASCPT Meeting in Atlanta on March 22nd. GFH312 is safe and well tolerated in healthy subjects in single or multiple doses with favorable PK /PD profile to support further clinical development.

As of July 2022, no grade 3 or above adverse effects were reported among all subjects. A rapid inhibition of RIPK1 phosphorylation in PBMCs was observed as soon as 2 hours post dosing in all dose groups and a sustained inhibition was achieved post multiple dosages. The data of cerebrospinal fluid (CSF) analysis from subjects receiving 120 mg daily administration suggest that GFH312 has exposure in the CNS and may potentially be useful for treating neurological indications. The phase I study of GFH312 was completed in Australia and GenFleet has been granted with the FDA approval for phase II study of GFH312.

"GFH312 is GenFleet's first clinical-stage product granted with FDA's IND approval for phase II study in non-oncology indication. The phase I study of GFH312 exhibited excellent safety/tolerability and fast inhibition of RIPK1 phosphorylation at the cellular level in subjects. RIPK1 is an important regulator of multiple signaling pathways in inflammation and necropoptosis. We hope to further explore multiple indications including neurological and inflammatory diseases." said by Yu Wang, M.D.,Ph.D., Chief Medical Officer of GenFleet.

A FIRST-IN-HUMAN PHASE I STUDY OF THE GFH312 A RIPK1 INHIBITOR, EVALUATING SAFETY/TOLERABILITY AND PHARMACOKINETICS IN HEALTHY SUBJECTS

Code: EP-032

This is a randomized (3:1), double-blinded, placebo-controlled first-in-human (FIH) study to assess safety/tolerability, pharmacokinetics and pharmacodynamics of GFH312 in healthy subjects, including seven single ascending dose (SAD) and three multiple ascending dose (MAD) cohorts. As of June 8, 2022, a total of 76 subjects have been enrolled into above dose levels. No grade 3 or above AEs were reported.

GFH312 was rapidly absorbed post a single oral dose with a median Tmax of 2 h ~ 8 h and eliminated with half-life of 6.3 ~ 23.3 h. Linear pharmacokinetic (PK) behavior was observed over the dose range from 45 mg to 360 mg. Limited accumulation was observed after multiple doses with accumulation ratio (RACmax and RAAUC) China (including Taiwan), the United States, Europe and Australia. To date, GenFleet has over 5 clinical studies encompassing IND stage to phase II studies and completed co-development partnerships with a number of publicly listed companies worldwide.

GenFleet is expected to progress additional programs into the clinic, as well as transition from a clinical stage biotech company into a commercial stage biopharmaceutical company in the next 3-5 years.

CONTACT: Yun Zeng, [email protected]

SOURCE GenFleet Therapeutics

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构